Suppr超能文献

促胰液素对正常和病理状态下β细胞的作用。

Effects of secretin on the normal and pathological beta-cell.

作者信息

Glaser B, Shapiro B, Glowniak J, Fajans S S, Vinik A I

机构信息

Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor 48109-0331.

出版信息

J Clin Endocrinol Metab. 1988 Jun;66(6):1138-43. doi: 10.1210/jcem-66-6-1138.

Abstract

Secretin is a gastrointestinal hormone that stimulates insulin secretion and enhances the insulin response to glucose. The mechanism by which secretin acts on the beta-cell has not been extensively studied. The plasma insulin responses to secretin (2 U/kg), expressed as the percent increase relative to basal plasma insulin concentrations, were similar in normal (n = 23) and obese subjects with normal glucose tolerance (n = 12), but were decreased in obese subjects with abnormal glucose tolerance (n = 11). The insulin response to secretin was directly proportional to the basal insulin concentration in these three groups. The effects of secretin on beta-cell function was not altered by propranolol (n = 6), atropine (n = 8), or surgical vagotomy (n = 10). Patients with single islet cell tumors secreting insulin (n = 18) had no plasma insulin response to secretin, whereas patients with noninsulin-secreting pancreatic tumors (gastrinomas; n = 6) and patients in whom single insulinomas had been removed (n = 7) responded normally. Two adult patients with multiple B-cell adenomas and hyperplasia (not associated with multiple endocrine neoplasia type I) hyperresponded to secretin, whereas patients with multiple endocrine neoplasia, type I, without hyperinsulinism responded normally. One patient with nesidioblastosis had no response to secretin, indicating that the pathophysiology of this entity is distinct from that of other forms of islet hyperplasia. These data suggest that secretin stimulates beta-cells directly rather than through cholinergic, adrenergic, or vagal peptidergic neural mechanisms. In addition, the ability to respond to secretin appears to be lost in patients with single insulinomas and nesidioblastosis, but not in those with multiple B-cell adenomas and hyperplasia. The lack of a plasma insulin response in patients with single insulinomas and the high normal or exaggerated response in patients with multiple B-cell adenomas and hyperplasia may prove useful in differentiating these entities.

摘要

促胰液素是一种胃肠激素,可刺激胰岛素分泌并增强胰岛素对葡萄糖的反应。促胰液素作用于β细胞的机制尚未得到广泛研究。正常受试者(n = 23)和糖耐量正常的肥胖受试者(n = 12)中,相对于基础血浆胰岛素浓度,血浆胰岛素对促胰液素(2 U/kg)的反应以增加百分比表示,二者相似,但糖耐量异常的肥胖受试者(n = 11)中该反应降低。在这三组中,胰岛素对促胰液素的反应与基础胰岛素浓度成正比。普萘洛尔(n = 6)、阿托品(n = 8)或手术切断迷走神经(n = 10)均未改变促胰液素对β细胞功能的影响。分泌胰岛素的单发性胰岛细胞瘤患者(n = 18)对促胰液素无血浆胰岛素反应,而无胰岛素分泌的胰腺肿瘤患者(胃泌素瘤;n = 6)和已切除单发性胰岛素瘤的患者(n = 7)反应正常。两名患有多发性B细胞腺瘤和增生(与I型多发性内分泌肿瘤无关)的成年患者对促胰液素反应过度,而无高胰岛素血症的I型多发性内分泌肿瘤患者反应正常。一名患有胰岛细胞增殖症的患者对促胰液素无反应,这表明该实体的病理生理学与其他形式的胰岛增生不同。这些数据表明,促胰液素直接刺激β细胞,而非通过胆碱能、肾上腺素能或迷走神经肽能神经机制。此外,单发性胰岛素瘤和胰岛细胞增殖症患者似乎丧失了对促胰液素的反应能力,但多发性B细胞腺瘤和增生患者则不然。单发性胰岛素瘤患者缺乏血浆胰岛素反应,而多发性B细胞腺瘤和增生患者反应正常或过度,这可能有助于区分这些实体。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验